PXD 118490

Drug Profile

PXD 118490

Alternative Names: LEO 80140; PXD118490

Latest Information Update: 29 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CuraGen Corporation; TopoTarget
  • Class Antipsoriatics
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psoriasis; Skin disorders

Most Recent Events

  • 23 Jan 2008 LEO Pharma discontinues development of PXD 118490; all rights to the compound revert to TopoTarget
  • 07 Nov 2006 Preclinical trials in Psoriasis in Europe (unspecified route)
  • 07 Nov 2006 Preclinical trials in Skin disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top